Status:
WITHDRAWN
Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department
Lead Sponsor:
University of Missouri, Kansas City
Collaborating Sponsors:
Truman Medical Center
Saint Luke's Hospital
Conditions:
Anaphylaxis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To determine if intravenous unfractionated heparin (with standard therapy) for treatment of anaphylaxis results in faster time to recovery.
Detailed Description
Anaphylaxis is a potentially life-threatening entity that requires both immediate recognition and aggressive treatment. Although anaphylaxis is infrequent, comprising only 1% of approximately 1.03 mil...
Eligibility Criteria
Inclusion
- 18 years and older
- English speaking
- Meets one of the above definitions of anaphylaxis
- Signs/symptoms onset \<12 hours will get epinephrine or will not get epinephrine because of contraindication to epinephrine administration.
Exclusion
- History of Intracranial Hemorrhage at anytime
- Known Cerebral Vascular Lesion (i.e. Aneurysm, Arteriovenous malformation)
- Ischemic CVA within the last 3 months
- Suspected Aortic Dissection
- Active Bleeding
- Known Bleeding/Clotting Disorder
- Closed Head Trauma within the past 3 months
- Major Surgery (Abdominal/Thoracic) within the last 3 weeks
- Active GI Bleeding
- Currently taking Warfarin
- Allergy to Heparins
- History of Heparin-induced Thrombocytopenia (AHA contraindications to fibrinolytic therapy 2005, Micromedix 2007)
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00657228
Start Date
December 1 2009
End Date
December 1 2010
Last Update
January 9 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Truman Medical Center ED
Kansas City, Missouri, United States, 64108
2
St. Luke's Hospital ED
Kansas City, Missouri, United States